{'52WeekChange': -0.88921285,
 'SandP52WeekChange': 0.0644362,
 'address1': '420 Saw Mill River Road',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 0.814,
 'askSize': 1400,
 'averageDailyVolume10Day': 4032750,
 'averageVolume': 2497780,
 'averageVolume10days': 4032750,
 'beta': 1.57535,
 'beta3Year': None,
 'bid': 0.75,
 'bidSize': 800,
 'bookValue': 6.429,
 'category': None,
 'circulatingSupply': None,
 'city': 'Ardsley',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 0.79,
 'dayLow': 0.7255,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.769,
 'enterpriseToRevenue': 1.157,
 'enterpriseValue': 203995984,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '914 347 4560',
 'fiftyDayAverage': 0.7917143,
 'fiftyTwoWeekHigh': 7.13,
 'fiftyTwoWeekLow': 0.65,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 43339041,
 'forwardEps': -2.03,
 'forwardPE': -0.3763054,
 'fromCurrency': None,
 'fullTimeEmployees': 344,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0149300005,
 'heldPercentInstitutions': 1.16935,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/acorda.com',
 'longBusinessSummary': 'Acorda Therapeutics, Inc., a biopharmaceutical '
                        'company, develops and commercializes therapies for '
                        'neurological disorders in the United States. The '
                        'company markets Ampyra (dalfampridine), an oral drug '
                        'to improve walking in patients with multiple '
                        'sclerosis (MS); and Selincro, an orally administered '
                        'drug for the treatment of alcohol dependence in '
                        'Europe. It also markets Ampyra as Fampyra in Europe, '
                        'Asia, and the Americas. In addition, the company '
                        'develops Inbrija for the treatment of OFF periods in '
                        "Parkinson's disease and ARCUS product for the "
                        'treatment of acute migraine. Further, it develops '
                        'rHIgM22, which has completed Phase I clinical trial '
                        'for the treatment of MS; and Cimaglermin alfa that is '
                        'in Phase Ib clinical trial for heart failure '
                        'patients. The company has collaboration and license '
                        'agreement with Biogen Inc. for the development and '
                        'commercialization of Ampyra. Acorda Therapeutics, '
                        'Inc. was founded in 1995 and is headquartered in '
                        'Ardsley, New York.',
 'longName': 'Acorda Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 36652760,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_24246',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -231832992,
 'nextFiscalYearEnd': 1640908800,
 'open': 0.79,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.01,
 'phone': '914 347 4300',
 'previousClose': 0.8017,
 'priceHint': 4,
 'priceToBook': 0.118820965,
 'priceToSalesTrailing12Months': 0.20781744,
 'profitMargins': -1.31447,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 0.79,
 'regularMarketDayLow': 0.7255,
 'regularMarketOpen': 0.79,
 'regularMarketPreviousClose': 0.8017,
 'regularMarketPrice': 0.79,
 'regularMarketVolume': 1797165,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 47981100,
 'sharesPercentSharesOut': 0.1901,
 'sharesShort': 9121053,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8389546,
 'shortName': 'Acorda Therapeutics, Inc.',
 'shortPercentOfFloat': 0.2649,
 'shortRatio': 3.72,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'ACOR',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.885,
 'twoHundredDayAverage': 1.173741,
 'volume': 1797165,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.acorda.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10502'}